‘Amazing' anti-ageing cream that reduces wrinkles in 7 days, leaving skin plump & smooth & it's half price at Boots
CUSTOMERS are raving about a drugstore anti-ageing cream that reduces wrinkles and leaves skin feeling smooth in 7 days.
With a bargain half price discount at Boots, customers have been quick to stock up on the popular product.
The Olay Regenerist Day Face Cream Moisturiser, Anti-Ageing Niacinamide and Peptides, is a staple for your skincare routine.
Its anti-ageing properties work to reduce fine lines and wrinkles, helping to smooth out your skin texture.
The Day Cream works best when applied to the face and neck in the morning, before applying the accompanying Night Cream before bed.
For those looking for a bit of sun protection they also offer a Day Cream containing SPF 30.
The product is described as a "luxurious face cream... designed to hydrate, firm and renew your skin, providing all-day hydration."
Using their Microsculpting technology combined with peptides and 99% pure niacinamide, it promises to penetrate 10 layers of the skin ensuring "visible skin regeneration".
With an average rating of 4.5 stars on the Boots web si te, the product is clearly a hit with skincare enthusiasts.
Some claimed that they always stock up when it's on sale, with eager shoppers able to purchase the product at Boots for just £15, reduced from its original £30.
One customer who said that they had been using the product for five years wrote: "obviously pleased with the ways it moisturisers and tightens skin."
Another said: " Amazing cream, makes your skin feel so soft, smells gorgeous, nice light cream... people have commented on my skin since I started using it."
'Why do you need all that-' fans beg to know as Princess Andre shares lengthy skincare regime that costs a whopping £160
Others were impressed that a drugstore brand had created such a high end product.
One wrote: "This cream initially feels like a high end beauty product with its luxuriously creamy consistency and pleasant perfume."
They did encourage other customers to make sure product was fully absorbed before moving on with the rest of their routine
It's part of Olay's wider range of Regenerist products which work together to keep skin looking refreshed.
Their accompanying Night Cream has similarly high reviews, with one shopper writing: "Best product for my skin on the market, tried cheaper and more expensive ones but this one is always on top!"
2
For those looking for even more effective benefits, the Regenerist Night Mask can be used 2-3 times a week on top of your usual routine to boost moisture and tighten your skin.
Similarly, their Ultra Rich Day Cream might provide an extra boost of moisture for those with dry skin.
For those with sensitive skin, the Fragrance-Free version might be a better alternative, with perfume and fragrance oils sometimes causing irritation.
If you're trying to be more environmentally-conscious, Olay have recently released refill versions of their most popular products.
Instead of throwing away your used containers, you can simply buy a refill pot and pop it in to the existing packaging, helping to reduce plastic waste and manufacturing emissions.
Olay's entire Regenerist range is currently available for half price online at Boots.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
an hour ago
- Times
Parent says no, stop the screen rot in schools
Bravo to the education committee for finally saying what we all know to be true: for young children, screens are like — and I'm paraphrasing here, but not by much — crack, in terms of rotting their brains and being ludicrously addictive. In its new report, 'Screen time: impacts on education and wellbeing', the committee concluded, 'The overwhelming weight of evidence submitted to us suggests that the harms of screen time and social media use significantly outweigh the benefits for young children.' In other words, it's not social media that's the problem. It's screens themselves. So, boy oh boy, that education committee will be really angry with whoever just made this decision: from September the national statutory tests for five-year-olds, the 'reception baseline assessment', will require at least two touchscreens — one for the teacher and one for the very young child (adult and child, side by side, both on screens, just as God intended.) Who on earth thought it was a good idea to test five-year-olds on tablets? Oh wait, it's written here in small letters, let me get my glasses …It was the Department for Education. Ah. By now, bodies ranging from the World Health Organisation to the NHS have published guidelines about screen time for young children. But these guidelines are arguably too little and definitely too late: a 2020 Ofcom report found that an astonishing 57 per cent of five- to seven-year-olds in Britain have a tablet. As a result of this large-scale outsourcing of parenting to screens, last week a coalition of schools, nurseries and colleges published a letter saying that children were now starting school with speech and emotional difficulties 'that are likely to have been exaggerated by or are even directly attributable to excessive screen time'. And yet the DfE has decided that those same screen-addicted kids should be tested on screens. And just to prove that too much screen time rots adults' brains too, I'm going to respond to this mess with an internet meme: DfE! Make! It! Make! Sense! • Schools issue parents with screen time limits from birth to age 16 So I emailed the department to ask — politely — what it was thinking. Why was it telling parents to give their kids less screen time while telling schools to give the kids more? Alas, to judge from the computer-says-no response I got, the DfE is now run by AI, which might explain its compulsion to test kids online: 'Digital assessments reduce the administrative burden on teachers, freeing up their time to focus more on teaching and supporting pupils' learning.' So young children will get to interact with teachers more by interacting with them less. Or something. Schools switched to digital learning during lockdown, and many found they enjoyed this easing of the 'administrative burden' so much, they never switched back. No surprise, given how much investment has been lavished on it: the UK-based primary school educational platform Atom Learning raised £19 million in 2021 and is now near ubiquitous. In April I wrote about the rise in primary schools of 'ed tech', aka education technology, aka teaching children via the medium of computer games, whizzy apps, tech portals and emojis. You don't need to be Mr Gradgrind to query the benefits of this gamification of education, teaching children from the age of five to expect lessons to be taught in ten-second bite-sized graphics. And we wonder why today's kids have such decimated attention spans. • Book holidays with bad wi-fi to get teens reading, says Winchester head Since then, I've heard some truly fascinating defences of education technology in primary schools. I was told that screens 'enrich students' learning experience', although when I asked if there was any proof of said enrichment, answer came there none. In fact, studies show that primary school kids experience what neuroscientists in one study describe as 'deeper reading' when learning from a paper text, whereas when they learn from a screen 'shallow reading was observed'. I was told that it's important to teach children how to use these devices for their future employment prospects, as though the devices weren't designed to be entirely intuitive, and addictive. And in any case, they will be utterly obsolete by the time these kids are in the workplace. Some argue that ed tech isn't social media, and that's true. But telling young children to do their school projects online is as ridiculous as telling them to do their homework in front of the TV: distraction is always a click away. And my personal favourite: 'The students really enjoy it.' They'd also enjoy eating sugar all day, so let's provide glucose on tap and see how that pans out. The one decent defence schools have for putting young kids on screens is that this is how they will increasingly be tested. Most GCSEs and A-levels will be online within a decade — so why not start them in primary school, seems to be the thinking. But five-year-olds are not 16-year-olds. One educator said to me breezily that this is simple 'market forces'. But schools — and certainly the DfE — should not be uncritical, passive consumers of tech. Mike Baxter, principal of City of London Academy, said last week, 'Over the past 20 years, schools and families have too often blindly trusted technology to aid and even enhance the education and wellbeing of our young people. However, the reality couldn't be further from this.' I have yet to meet anyone who can explain why it's better for children to write an essay online and upload it to Google Classroom than write one by hand in a notebook. If schools can't say how any of this benefits the pupils, they shouldn't do it. Computers aren't the only thing that can say no.
Daily Mail
3 hours ago
- Daily Mail
NHS patients battling Alzheimer's WON'T be offered 'miracle' drugs as health watchdog rules they are 'too expensive to justify'
Two of the first drugs proven to slow down Alzheimer's disease will be denied to NHS patients from this week - unless they pay to go private. The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use on the NHS as they are too expensive to justify. This means over 70,000 patients in England will be denied the 'game-changing' drugs, found to slow cognitive decline by an average of four to seven months, unless they can afford tens of thousands of pounds a year for private treatment. After a positive drug trial in 2022, lecanemab (brand name Leqembi) made by Eisai, and donanemab (marketed as Kisunla), made by Eli Lilly, were proven to clear toxic amyloid protein from the brain and thus slow the underlying cause of dementia. Campaigners hailed it as 'the beginning of the end' of Alzheimer's. Iain Hartnell, Research Communications Officer at Alzheimer's Society, said: 'The MHRA's approval of the first safe and effective Alzheimer's disease treatment, shown to slow progression, is a defining moment for people with early-stage Alzheimer's disease in the UK and a significant step towards a more hopeful future.' Last year, both drugs were given drug licences in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). But without NICE's recommendation, the groundbreaking medicine will only be available to those with private healthcare. 'It is the end of the road for these drugs on the NHS,' an insider told The Times. Hilary Evans-Newton, the chief executive of Alzheimer's Research UK described the decision as 'deeply disappointing'. She told the publication that it sends 'a damaging signal to the life sciences sector - undermining confidence in the UK as a leader of dementia research, clinical trials and innovation, with knock-on effects for patients and the wider economy'. She added: 'These treatments are not perfect, and we recognise the challenges they pose around cost, delivery and safety. But scientific progress is incremental, and these drugs represent a vital foundation to build on.' The drugs were shown in trials to slow the rate of decline for those with mild to moderate Alzheimer's by an average of four to seven months. Lecanemab, for example, can slow the decline in memory and mental agility by 27 per cent in those with mild Alzheimer's taking the drug compared to people on the dummy drug. The research team also found that the drug reduced loss of quality of life by up to 56 per cent, according to the Alzheimer's Society. Importantly, the drug reduced the amount of amyloid protein present in the brain. Amyloid protein levels were also reduced in the blood and spinal fluid. Experts have long believed donanemab could herald a new era of dementia treatment, after studies showed it slowed the memory-robbing illness in its early stages Lecanemab has already been given the green light in the EU, US, China, Japan, Hong Kong, South Korea and Israel. It is estimated around 70,000 adults in England could eligible for the treatment if approved for use on the health service. Alzheimer's is the most common cause of dementia in the UK. Around 982,000 are currently estimated to be living with dementia UK - although this figure is expected to skyrocket to 1.4million in 2040. Alzheimer's Research UK analysis found 74,261 people died from dementia in 2022, compared to 69,178 a year earlier, making it the country's biggest killer. Recent analysis by the Alzheimer's Society estimates the overall annual cost of the dementia to the UK is £42billion a year, with families bearing the brunt. An ageing population means these costs — which include lost earnings of unpaid carers — are set to soar to £90billion in the next 15 years.
Daily Mail
3 hours ago
- Daily Mail
The secrets to beating the 8am scramble for GP appointments by the people who really know - the receptionists! And at least one of them is VERY surprising...
The secrets to beating the 8am scramble for GP appointments by the people who really know - the receptionists! And at least one of them is VERY surprising... They're often painted as the grim-faced gatekeepers of the overstretched NHS. Manning the phone lines to surgeries, GP receptionists have long borne the brunt of patients' growing frustration with the primary care system.
